Search

To evaluate Gadomer-enhanced magnetic resonance (MR) imaging in the quantification of small microvascular obstruction regions and determine if nicroandil alleviates the formation of microvascular obstruction.Approval of the institutional committee on animal research was obtained, and this study complied with guidelines for care and use of animals. Rats underwent coronary artery occlusion and reperfusion. After 24 hours, Gadomer-enhanced T1-weighted spin-echo MR imaging was used to define microvascular obstruction in animals in control and nicorandil groups. Sequential MR images obtained at two midventricular levels were acquired to measure microvascular obstruction and ischemically injured regions and monitor diffusive and/or convective transport of Gadomer in microvascular obstruction regions. Two investigators working in consensus and using threshold signal intensity measured differentially enhanced regions. Left-ventricular (LV) end-systolic and end-diastolic MR images obtained at the same two midventricular levels were used to measure regional wall thickening and systolic reduction in LV relative volumes. Agreement and correlation between MR imaging and postmortem data were determined with Bland-Altman and linear regression analyses. Animals were sacrificed 3 minutes after intravenous injection of blue dye.On Gadomer-enhanced MR images, two differentially enhanced regions were observed in ischemically injured myocardium, namely, the hypoenhanced region and the surrounding hyperenhanced region. Hypoenhanced regions at MR imaging and unstained regions at blue dye administration were identical 3 minutes after administration (17% +/- 1 and 17% +/- 2; P = .6; r = 0.98). In the control group, Gadomer provided a prolonged imaging window (eg, 6 minutes) for accurately quantifying small microvascular obstruction regions. Microvascular obstruction was observed in all animals in the control group and 27% of animals in the nicorandil group. Microvascular obstruction regions were smaller in the nicorandil group (eg, 3% +/- 1) than in the control group (eg, 17% +/- 2) (P.001). Hyper- and hypoenhanced regions were also smaller (eg, 20% +/- 2) in rats in the nicorandil group than in those in the control group (37% +/- 4, P.001). Improvement in LV function in the nicorandil group is likely related to alleviation and reduction in infarct size.Gadomer-enhanced MR imaging can be used to quantify small microvascular obstruction regions 24 hours after reperfusion. Intravenous therapy with nicorandil reduces formation of microvascular obstruction regions.

To assess the feasibility of percutaneous magnetic resonance (MR)-guided intramyocardial injection of gadodiamide by using real-time imaging and to quantify T1 values and the size of the enhanced region for different concentrations of contrast agent for 30 minutes after injection.Animal care committee approval was obtained. A catheter with a needle tip was advanced into the left ventricle in seven pigs by using real-time imaging with radial steady-state free precession. After intramyocardial injection of 2 mL of solution at concentrations of 0.05 or 0.10 mmol/mL gadodiamide, local changes in T1 values and size of the contrast material-enhanced region were sequentially measured at 3, 15, and 30 minutes after injection by using the Look-Locker sequence. Two-tailed paired Student t tests were used for statistical analysis.Catheter guidance and visualization of contrast agent distribution were feasible in all animals. Regional changes in T1 values were significantly different for different contrast agent concentrations (for 0.05 mmol/mL, 456 msec +/- 5 [+/- standard error of the mean]; for 0.10 mmol/mL, 228 msec +/- 4; P.001) measured 3 minutes after injection. T1 values increased significantly (P.05) to 720 msec +/- 7 for 0.05 mmol/mL gadodiamide and 445 msec +/- 6 for 0.10 mmol/mL gadodiamide 30 minutes after injection but remained significantly lower than those of remote myocardium (879 msec +/- 8). The size of the contrast-enhanced region increased from 13 mm(2) +/- 2 at 3 minutes to 30 mm(2) +/- 3 at 30 minutes (P.05).Catheter MR-guided percutaneous intramyocardial injection is feasible; after intramyocardial injection of gadodiamide at concentrations of 0.05 and 0.10 mmol/mL, T1 values decreased over the observation time.

To demonstrate the feasibility of using a combination of x-ray fluoroscopic and magnetic resonance (MR) fluoroscopic (ie, x-ray/MR fluoroscopy) guidance for left ventricular (LV) catheterization and transendocardial delivery of extracellular tissue markers.Experiments were performed in six dogs by using an x-ray/MR fluoroscopy system. The arterial guide wire and catheter were advanced into the heart with x-ray fluoroscopic guidance. The dogs were injected with 0.5, 1.0, and 2.0 mL of iohexol. For passive catheter tracking, a steady-state free precession MR imaging sequence was used. A steerable dual-lumen catheter was used to transendocardially inject a mixture of gadodiamide (0.05 mol/L) plus Evans blue dye (3%). An electrocardiographically gated dual-inversion-recovery MR imaging sequence was used to visualize the myocardial delivery of the gadodiamide-blue dye mixture. A high concentration of gadodiamide (0.5 mol/L) was used to demarcate the borders of the area of interest, or "hit the target." Blood pressure, heart rate, and oxygen saturation were measured before and after the intervention. Analysis of variance, Scheffé, and paired Student t tests were used for data analysis.LV catheterization via arterial access was feasible with two-dimensional x-ray fluoroscopic and three-dimensional MR fluoroscopic guidance. Delivery of the gadodiamide-blue dye mixture and the consequences of the procedure were monitored with MR imaging. Gadolinium-enhanced regions were bright on T1-weighted MR images, but they varied in size as a function of injectant volume. The mean sizes of these regions were 1.5% +/- 0.6 of the LV after the 0.5-mL injection of the mixture and 7.0% +/- 0.5 of the LV after the 2.0-mL injection (P.001, Scheffé test). The corresponding mean sizes of the blue dye-enhanced regions were 2.3% +/- 0.6 and 8.3% +/- 0.4, respectively (P.001). A high concentration of gadodiamide caused signal intensity loss around the gadolinium-enhanced regions.Transendocardial delivery of potential therapeutic solutions is feasible with x-ray/MR fluoroscopic guidance. The injection catheter can be navigated with MR imaging guidance to hit the target.

To assess the feasibility of using magnetic resonance (MR) imaging to guide stent deployment in the pulmonary valve and artery and evaluate, after stent deployment, the position and morphology of and blood flow through the stent.Angiography and 1.5-T MR imaging were performed in a dual-imaging suite. Nitinol stents were placed in the pulmonary valve and main pulmonary artery in five pigs by using MR imaging guidance. For interactive MR imaging monitoring of catheter manipulation and stent delivery, balanced fast field-echo and T1-weighted turbo field-echo sequences were used. Visualization of the delivery system was based on T2* (with air as the contrast material) or T1 (with gadodiamide as the contrast material). After stent deployment, the position and morphology of and flow through the stent were verified with multiphase multisection balanced fast field-echo and velocity-encoded cine MR imaging. Findings at angiography and postmortem examination also helped verify stent placement. The paired Student t test was used for data analysis.The stent was successfully deployed in all animals. The stent was placed distal to the pulmonary valve in four animals and across the pulmonary valve in one animal. The position and morphology of the stent were clearly depicted on balanced fast field-echo images. In the animal with the stent placed across the pulmonary valve, the pulmonary regurgitant fraction was 37%; this was not seen in the animals with stents placed distal to the pulmonary valve. No complication (eg, stent migration, intramural injury, or vascular perforation) was noted during the intervention. Findings at angiography and postmortem examination confirmed the position of the stents.MR imaging has the potential to guide stent placement in the pulmonary valve or artery and to evaluate flow volume within the stent lumen after the intervention.

To evaluate the feasibility of magnetic resonance (MR) imaging-guided placement of an active vena cava filter (AVCF) in a swine model, the effectiveness of the system in filtering thrombi, and the detection of thrombi with MR imaging.This study was approved by the government committee on animal investigations. An AVCF tuned to the Larmor frequency of a 1.5-T MR unit was placed in the inferior vena cava (IVC) of seven pigs under real-time MR imaging guidance. Steady-state free precession sequences with four different flip angles (90°, 40°, 25°, and 15°), T1-weighted turbo spin-echo sequences with two flip angles (90° and 15°), and black-blood proton-density-weighted sequences with a flip angle of 90° were performed before and after filter placement. In six cases, extracorporeally produced thrombi were injected through the femoral access to test filter function. The signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) were assessed before and after filter deployment and compared by using the signed-rank test.All AVCFs were successfully deployed. Significant differences (P.05) in the SNR and CNR of the IVC were found before and after AVCF placement and between sequences with different flip angles. Intravenous thrombi were caught in all cases and clearly depicted with MR imaging. On black-blood proton-density-weighted images, high-signal-intensity thrombi inside the filter were clearly detectable without any overlaying artifacts.MR imaging-guided deployment and monitoring of an AVCF is feasible. The AVCF enhances the SNR and CNR, resulting in clear depiction of thrombi inside the filter without the need for contrast material. Design modifications for improved intracaval fixation and retrieval of the prototype AVCF will be required.

To determine whether stunned myocardium can be delineated at magnetic resonance (MR) imaging with differential cellular uptake of manganese ions.Twenty-one adult Sprague-Dawley rats underwent either (a) a sequence of three episodes of 10 minutes of coronary artery occlusion and 12 minutes of reflow (group 1, n = 9); (b) a single episode of 10 minutes of occlusion followed by reflow (group 2, n = 6), designed to produce different degrees of myocardial stunning; or (c) a single episode of 2 minutes of occlusion followed by reperfusion (group 3, n = 6), designed to produce no stunning. Ventricular wall thickening was measured on spin-echo (SE) MR images. MnCl2 (0.025 mmol/kg) was intravenously infused for 10 minutes. Highly T1-sensitive inversion-recovery (IR) SE images were obtained to detect subtle regional differences in manganese accumulation. Hearts were stained at sacrifice to define area at risk and to test for myocardial infarction. Significance of differences in mean values was evaluated with repeated-measures analysis of variance.All hearts were free of infarction, as detected with triphenyltetrazolium chloride staining. On IR SE images, the hearts from rats in groups 1 and 2 exhibited clearly delineated regions of diminished manganese uptake in the expected territory of the occluded artery. The circumferential extent of the manganese-defined defect (45.5% +/- 5.6) was similar to that of the area at risk (46.8% +/- 7.5). Systolic wall thickening in the defect was significantly (P.01) less than in the nonischemic myocardium (2.7% +/- 3.3 vs 31.2% +/- 7.5 and 10.0% +/- 4.8 vs 28.6% +/- 6.5, respectively, for groups 1 and 2). The hearts from rats in group 3 demonstrated no wall thickening deficit or abnormal zone on manganese-enhanced images.Stunned myocardium was delineated with MnCl2-enhanced MR imaging as a hypoenhanced zone. This finding suggests that Ca2+ channel activity is diminished in stunned myocardium.

To (a) assess the value of a blood pool magnetic resonance (MR) imaging contrast agent (Clariscan) for characterizing microvascular injury in ischemically injured rat myocardium and (b) compare the extent of microvascular injury at Clariscan-enhanced MR imaging with infarction and areas at risk seen with histochemical staining.Twenty rats underwent 45 minutes of coronary artery occlusion and 3 hours of reperfusion. Sequential T1-weighted spin-echo MR images were acquired in 10 rats to assess leakage of Clariscan into myocardium over time. Ten other rats underwent the same duration of occlusion and reperfusion (3 hours) so that the extent of microvascular injury in the entire heart could be measured and correlated with infarction and area at risk at necropsy. The Student t test and Bland-Altman method were used for data analysis.Clariscan improved visualization of regions with transmural and nontransmural microvascular injury. Accumulation of Clariscan was best reflected by the mean ratios of signal intensity in injured myocardium to that in normal myocardium measured before (0.98 +/- 0.01 [standard error of the mean]) and after (1.34 +/- 0.04) injection. At 15 minutes after injection, the size of the enhanced region remained constant over the course of observation. The mean size of the hyperenhanced region (44% of the left ventricle +/- 2) was significantly (P.001) larger than the mean size of true infarction at necropsy (29% +/- 3) but smaller than the mean size of the area at risk (50% +/- 2).Clariscan has potential for estimating the spatial extent of microvascular injury in ischemically injured myocardium and may be useful as a marker of microvascular injury after thrombolytic therapy.

To use magnetic resonance (MR) imaging in quantification of the short- and long-term effects of therapy with orally administered nicorandil on left ventricular (LV) geometry and function independent of infarction size.Forty-six rats were subjected to reperfused infarction and randomly divided into two groups. Group 1 rats (n = 21) were treated with nicorandil (3 mg/kg/day in drinking water) for 4 days before infarction and 8 weeks after infarction (hereafter, the nicorandil group). Group 2 rats (n = 25) received tap water for the same period and served as the control group. Mesoporphyrin- (as a necrosis-specific agent) enhanced MR imaging was used to define necrotic myocardium on day 2 after infarction in all 46 animals. Contrast material-enhanced MR images showed large but identical infarction size in 11 control and 11 nicorandil rats. Only these 22 rats underwent repeat MR imaging at 8 weeks after infarction. The following variables were measured: LV volumes, ejection fraction, mass, wall thickness, and infarction size. Student t test and analysis of variance for repeated measurements were used for statistical analysis.The size of the necrotic region on mesoporphyrin-enhanced MR images was 39% +/- 3 of the size of the left ventricle in the control group and 41% +/- 2 in the nicorandil group (difference not significant, unpaired Student t test). Pretreatment with nicorandil for 6 days before imaging did not reduce LV dilation or improve function compared with those in control animals with identical infarction size. Eight weeks after infarction, control animals showed deterioration in LV function, wall thinning, and gradient in regional dysfunction (analysis of variance test). Nicorandil produced significant salutary effects on LV ejection fraction (37% +/- 3 in the nicorandil group vs 24% +/- 3 in the control group), end-diastolic volume (0.53 mL +/- 0.03 vs 0.65 mL +/- 0.04), end-systolic volume (0.36 mL +/- 0.03 vs 0.49 mL +/- 0.05), LV wall thickening in remote noninfarcted myocardium (28% +/- 2 vs 19% +/- 1), and a rim of infarction (16% +/- 2 vs 8% +/- 1) (P.05 for all parameters). The increase in LV mass was reduced in the nicorandil group (0.73 g +/- 0.03) compared with that in the control group (0.89 g +/- 0.04) (P.05).In animals studied longitudinally, MR imaging demonstrated the deleterious changes in LV geometry and function in the period after infarction and the salutary effects of medical therapy.